# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10532690		
Filing Date		2006-04-26		
First Named Inventor	Kırvin	L. Hodge		
Art Unit		1614		
Examiner Name	L. Zhi	ang		
Attorney Docket Numb	er	18028-PCTUS		

				U.S.	PATENTS	Remove
Examiner Initial* Cite No Patent Num		Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	7101910	B2	2006-09-05	Sharma	
	2	6924314	B2	2005-08-02	Sharma, et al.	
	3	6858602	B2	2005-02-22	Sharma, et al.	
	4	7045541	B2	2006-05-16	Sharma	
	5	7041659	B2	2006-05-09	Sharma	
	6	6916848	B2	2005-07-12	Sharma	
	7 6946491 B2 200		2005-09-20	Sharma, et al.		
	8	7012071	B2	2006-03-14	Sharma, et al.	
you wis					lease click the Add button.	L

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10532690		
Filing Date		2006-04-26		
First Named Inventor Kırvin		L. Hodge		
Art Unit		1614		
Examiner Name L. Zha		ang		
Attack Dealer Month	nr.	19029 DCTUS		

			U.S.P	AIENI	APPLI	CATION PUB	LICATIONS		HEITIOVE	
Examiner Initial*	taminer Cite No Publication Number Kind Publication Name of Patentee or Applicant of cited Document			Releva	,Columns,Lines wh ant Passages or Re as Appear					
	1	20050256333	A1	2002-11	I- <b>1</b> 7	Sharma, et al.				
	2	20050090555 A1 2005-04-28 Sharma, et al.								
	3	20060247309	A1	2006-11-02 Hodge, et al.						
	4	20060014784	A1	2006-01	I- <b>1</b> 9	Hodge, et al.				
If you wish	h to a	dd additional U.S. Publi	shed Ap					d buttor		
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Examiner Cite Foreign Document Country Kind Publication Name or settled where Relevant					Passages or Relev	Ts			
	1	2006/127133	wo		A2	2004-05-21	Hodge, et al.			
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the ar (book, magazine, journ publisher, city and/or of	nal, seria	al, symp	osium,	catalog, etc), o				n Ts
	1 Pending (as of March 26, 2007) claims from U.S. Application No. 11/535,779.									

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10532690		
Filing Date		2006-04-26		
First Named Inventor Kırvin		L. Hodge		
Art Unit		1614		
Examiner Name L. Zha		ang		
Attorney Docket Number		18028-PCTUS		

	2	Pend	ing (as of March 26, 2007) claims from U.S. Application No. 10/554586.						
	3	Pend	Pending (as of March 26, 2007) claims from U.S. Application No. 10/559936.						
	4 Pending (as of March 26, 2007) claims from U.S. Application No. 10/566302.								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE									
Examiner	Signa	ature	Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with part communication to applicant									

See Kind Code of USPTO Patient Documents at year USPTO\_CODY or MPEP 901.04. <sup>2</sup> Either office that issued the document, by the ho-eleter code (WIPO Standard ST.3.) <sup>2</sup> For Juraprese patient Counters, by the action of the year of the response must proced the sears inwarbor of the patient document, and any other patient of the propriet must proceed be sears inwarbor of the patient document.

\*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>3</sup> Applicant is to place a check mark here if English targuages the restation is distanced.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10532690
Filing Date		2006-04-26
First Named Inventor	Kırvin	L. Hodge
Art Unit		1614
Examiner Name	L. Zha	ang
Attorney Docket Numb	er	18028-PCTUS

#### CERTIFICATION STATEMENT

Diagra can	37	CFR .	97	and	1 02	to make	the	appropriate	colortion/c	'n

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97.0F4.137(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ Nor

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lewis J. Kreisler/	Date (YYYY-MM-DD)	2007-03-30
Name/Print	Lewis J. Kreisler	Registration Number	38522

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol field not by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 231-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.